Rochester, NY 8/31/2009 4:50:30 PM
ACADIA Pharmaceuticals, Inc. ACAD, End of the Report market trade down at 1.16%
ACADIA Pharmaceuticals, Inc. ACAD
ACADIA Pharmaceuticals, Inc. Ends the day at $ 5.98 amounting loss of 7 cents or 1.16%. It hits on posted volume of 1,239,160. The company stocks still off a 52-week high of $6.60.
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders.
http://StockEinstein.com offers free daily stock alerts on companies ready to run. Scroll to BOTTOM of this page for free stock alerts, or visit our site.
Last Trade: 5.98
Day's Range: 5.91 - 6.14
52wk Range: 0.72 - 6.60
Change: 0.00 (0.00%)
Volume: 0
Avg Vol (3m): 1,239,160
ABOUT ACADIA Pharmaceuticals, Inc.
ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It focuses on developing a portfolio of its four advanced product candidates, including Pimavanserin, which is in phase III development for Parkinson's disease psychosis; and a product candidate in phase II for chronic pain and a product candidate in phase I for glaucoma, each in collaboration with Allergan, Inc., as well as ACP-106 in IND-track development for neuropsychiatry and sleep indications. Pimavanserin is also in a phase II trial as a co-therapy in schizophrenia and in a proof-of-concept clinical study for sleep maintenance insomnia. ACADIA Pharmaceuticals development pipeline also consists of ACP-105 for endocrine indications in IND-track development stage; Serotonin program for neuropsychiatry and sleep indications in preclinical stage; pro-cognitive antipsychotic (PCAP) program for schizophrenia in preclinical stage; Muscarinic program for neuropsychiatry and other indications; and two series of compounds for Parkinson's disease. It has a collaboration agreement with Biovail Laboratories International SRL to co-develop and commercialize pimavanserin in the United States and Canada. The company, formerly known as Receptor Technologies, Inc., was founded in 1993 and is headquartered in San Diego, California.
About Stock Einstein
StockEinstein uses proprietary technologies coupled with years of experience to uncover stocks we feel have the greatest potential for breakout performance. We utilize not only software, but time tested criteria to uncover these potential winners. When these benchmarks are reached or exceeded, our subscribers are immediately notified.
This service is free and available only to subscribers. Scroll to the bottom of this page to signup for free stock alerts and visit our site.Disclaimer: Full disclaimer at http://StockEinstein.com/disclaimer.php
IMPORTANT: Never invest in any stock featured in any press release, email or website unless you can afford the loss of your entire investment. Stocks and particularly penny stocks have the possibility for dramatic gains, and also losses. Neither StockEinstein, nor any of its affiliates are registered investment advisors or broker dealers.
